Science

Articles

• Harnessing TfR1 for Cross-Species Systemic Delivery of siRNAs to Deep Brain Regions Using Single-Domain Antibodies
  26 May, by Emmanuelle BETTENDORF

  Our latest preprint demonstrating the ability of the VECTrans® platform to deliver therapeutics, particularly oligonucleotides, to deep regions of the brain at clinically viable doses has just been published by bioRxiv.
  The research by @Guillaume Jacquot and the Vect-Horus team details the unique functions of our technology platform to transport oligonucleotides across the blood-brain barrier and open up new avenues for the treatment of diverse central nervous system disorders. (…)

• Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
  22 April 2024, by Emmanuelle BETTENDORF

  Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
  The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides (…)

• Meet Vect-Horus at Deeptech in Glioblastoma Symposium
  13 January, by Emmanuelle BETTENDORF

  Cédric Malicet, our Oncology Program Director, will be taking part in a panel discussion at the DeepTech in Glioblastoma conference, organized by Paris Saclay Cancer Cluster (PSCC), and taking place January 22 in Villejuif, France.
  Cedric will participate in a pitch session entitled “A comprehensive and diverse front against glioblastoma”, along with representatives from Carthera, TheraSonic, Robeauté, Innov’nCare , with the discussion moderated by Professor Ahmed Idbaih .
  It takes place (…)

• How blood–brain barrier technology is unleashing CNS therapies
  19 September 2025, by Emmanuelle BETTENDORF

  Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
  It’s well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
  It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

• Vect-Horus appoints Claudia Fromond as new Director of R&D
  10 March, by Emmanuelle BETTENDORF

  We are very pleased to welcome Claudia Fromond to Vect-Horus as our new Director of R&D.
  Claudia is a highly regarded pharmacology and translational science leader with extensive experience in R&D. She has successfully overseen first-in-class programs from discovery to Investigational New Drug (IND) application and early clinical development, including a portfolio of seven IND-enabling programs which achieved Phase 1/2 readiness.
  “Claudia has a proven track record of successfully (…)

• Vect-Horus successfully completes the VECtoBrain project
  28 January 2019, by Jonathan NOWAK

  Ths project was supported from 2009 to 2013 by the Agence Nationale de la Recherche (ANR) BiotecS Call 2009.
  The project was coordinated by VECT-HORUS (Dr. Guillaume Jacquot) and involved the UMR7259 laboratory (CNRS and Aix-Marseille University, Director Dr Michel Khrestchatisky), the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA.
  This project also received support (label) from the EUROBIOMED Biocluster.

• New PCT patent application covering anti Transferrin receptor vectors
  13 October 2020, by Elodie DORMES

  Vect-Horus has filed a PCT patent application covering a library of vectors that target the Transferrin receptor (TfR). This patent strengthens the intellectual property of the Company with a portfolio containing now 6 patent families. This confirms its position as a major player in Blood-Brain Barrier drug delivery technology.

• How blood–brain barrier technology is unleashing CNS therapies
  18 March 2025, by Emmanuelle BETTENDORF

  We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.
  This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.
  Click below for the full article.
  👉 (…)

• Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
  15 May 2024, by Emmanuelle BETTENDORF

  The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
  The study showed that these vectors have the potential to improve delivery of medication to the (…)

• Vect-Horus will participate to the “R&D Seminar IMAGING 2022” organized by the Cerimed September 26-30, 2022
  26 September 2022, by Elodie DORMES

  VECT-HORUS S.A.S. will participate in the next event dedicated to Imaging and organized by CERIMED: “R&D Seminar IMAGING 2022” from Monday, 26th September to Friday 30th September.
  Cedric MALICET will give a talk, « From bench to Clinic », Thursday, 29th September in the workshop intitled “NUCLEAR MEDICINE Imaging”.
  It will be the occasion to present Vect-Horus technology, the last imaging results generated by in vitro and in vivo TEP with our #LDLR vectors currently in clinical study (…)